Presentation on theme: "‘Cohort multiple RCT’ design workshop Clare Relton & Jon Nicholl School of Health and Related Research (ScHARR) Faculty of Medicine University of Sheffield."— Presentation transcript:
‘Cohort multiple RCT’ design workshop Clare Relton & Jon Nicholl School of Health and Related Research (ScHARR) Faculty of Medicine University of Sheffield
Purpose of workshop Share knowledge, experiences and ideas
Programme Introduction to the cmRCT design Current research using the design Panel Q&A LUNCH How to analyse cmRCTs Talking Circles I & II (35 mins each) Tea/coffee 15.20Plenary feedback/ Panel discussion 16.30End
Housekeeping Exits Loos Name No mobiles Workshop information Talking circle topics
Introduction to cmRCT design Problems with standard designs cmRCT design defined Differences with other designs Benefits Most suited to.....
Pragmatic trials ‘pragmatic’ first applied to clinical trials by Schwartz & Lellouch (1967) who made the distinction between: explanatory trials (which aim to further knowledge as to how and why) pragmatic/practical trials (which aim to inform healthcare decisions within routine practice).
Problems with standard designs poor recruitment rates – implications for cost, validity, reliability, comparability of the results informed consent barrier to recruitment (Ross, 1999) unrepresentative recruited population patient & clinician treatment experiences altered lack of long term outcomes poor external validity....
Components of cmRCT *1 Cohort * 2 Random selection * 3 Informed consent – patient centred
* 1: Cohort Recruit observational cohort of patients Regular outcome measurement for whole cohort
* 2: Random selection Capacity for multiple RCTs over time For each RCT eligible patients identified from which some randomly selected to be offered the intervention Outcomes of randomly selected patients compared to not randomly selected.
* 3: Informed consent Patient information and consent replicate real world routine healthcare i.e. patients are not told about treatment that they might not receive
*1. Cohort Characterised/ phenotyped population’ Contacted again Use their data comparatively Access to routine health records Facility for multiple trials
*2. Randomisation Something that is ‘done’ to everyone? Random allocation of all Or Random selection of some
*3. Informed Consent
Memory research Many people suffer from poor memory and there are few treatments available However, US research has found that as well as helping lower blood pressure (Buitrago-Lopez 2011), chocolate (epicatechin) can boost memory in mice particularly when combined with exercise. University of Sheffield researchers are now planning a study to measure the effectiveness of chocolate on memory. We (researchers) are looking for people to participate in this research. If you decide to participate you will be asked to provide information about your general health and physical activity (using an online form) and asked to perform a short online memory test once a week for 6 weeks. We are not sure if chocolate is more effective than no chocolate. Participants will be randomly selected to receive either chocolate or no chocolate
*3. Informed Consent Patient centred Replicates procedures in routine healthcare Patients not told about treatments that they are not then offered Patients not told that their treatment will be chosen ‘at random’
09/05/2015 (II) …and there is research ongoing… (III) … and we want to observe you…. (IV) …and we are not sure which treatment is best…. (V) …and we are going to play a game of chance’… (I) There is a treatment and the benefits are… the risks are … Type and timing of information (standard RCT design)
09/05/2015 (II) …there is research ongoing… (III) … and we want to observe you…. (IV) …and we are not sure which treatment is best…. (V revised) …and you have been selected at random to try it.... (I) There is a treatment and the benefits are… the risks are … Type and timing of information: ‘patient centred’ as used in ’cmRCT’ design
Benefits of ‘cohort multiple RCT’ approach Recruitment – improved quantity and more representative sample multiple RCT facility long term outcomes as standard ongoing information as to the natural history of the condition and treatment as usual increased comparability between each trial conducted within the cohort increased efficiency, particularly for expensive or high risk interventions (unequal randomisation)
Opportunities Open trials with ‘treatment as usual’ as comparator Easily measured & collected outcomes Clinical conditions where many trials will be conducted Chronic conditions Highly desired treatments or expensive treatments
Least suited to.. Closed trial designs with masking or placebo arms Research questions with hard to measure and hard to collect outcomes Acute or short term conditions